Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy

PURPOSE: We aimed to assess the patient-reported outcome (PRO) and efficacy of add-on low-dose antimuscarinic therapy in over-active bladder (OAB) patients with suboptimal response to 4-week treatment with beta 3 agonist monotherapy (mirabegron, 50 mg). MATERIALS AND METHODS: We enrolled OAB patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jung Hyun, Kim, Aram, Choo, Myung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494350/
https://www.ncbi.nlm.nih.gov/pubmed/28681036
http://dx.doi.org/10.4111/icu.2017.58.4.261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494350/
https://www.ncbi.nlm.nih.gov/pubmed/28681036
http://dx.doi.org/10.4111/icu.2017.58.4.261

Ejemplares similares